SAN DIEGO--(BUSINESS WIRE)--Dec. 7, 2018--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, will hold a conference call on December 10, 2018 to
discuss the San Diego Superior Court’s ruling related to Quidel’s BNP
Supply Agreement with Beckman.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will host an investment community
conference call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific
Time) on Monday, December 10th to discuss the outcome. During the
conference call, management may answer questions regarding the intended
ruling. Quidel’s responses to these questions, as well as other matters
discussed during the conference call, may contain or constitute material
information that has not been previously disclosed.
To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and enter the
audience pass code 846-3868.
A live webcast of the call can be accessed on the Investor Relations
section of the Quidel website (http://ir.quidel.com).
The website replay will be available for 14 days. The telephone replay
will be available for 48 hours beginning at 10:00 a.m. Eastern Time
(7:00 a.m. Pacific Time) on December 10, 2018 by dialing 855-859-2056
from the U.S., or by dialing 404-537-3406 for international callers, and
entering pass code 846-3868.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as
well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic
brands, Quidel’s products aid in the detection and diagnosis of many
critical diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease
and fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC), offering
a diverse immunoassay menu in a variety of tests to provide healthcare
providers with diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s research
and development engine is also developing a continuum of diagnostic
solutions from advanced immunoassay to molecular diagnostic tests to
further improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about Quidel’s
comprehensive product portfolio, visit quidel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181207005587/en/
Source: Quidel Corporation
Media and Investors Contact: